The hepatitis B vaccine is recommended for anyone at increased risk of exposure to the hepatitis B virus — including travellers to high-prevalence regions, healthcare workers, people who inject drugs, those with certain medical conditions, and individuals whose sexual behaviour puts them at risk. In the UK, hepatitis B vaccination has been part of the NHS childhood immunisation schedule since 2017, meaning that children born from that year onwards receive the vaccine as standard — but many adults remain unvaccinated and may be unaware of their risk. Hepatitis B is one of the most common serious liver infections in the world, with over 254 million people living with chronic hepatitis B globally according to the WHO Global Hepatitis Report 2024, and it is responsible for approximately 1.1 million deaths annually — the majority from cirrhosis and liver cancer. At Perfect Meds, our GPhC-regulated pharmacists offer comprehensive hepatitis B vaccination services, including assessment of your individual risk, administration of the full vaccine course, and follow-up antibody testing to confirm that protective immunity has been achieved.
Book now to arrange your hepatitis B vaccination at Perfect Meds.
The hepatitis B vaccine is recommended for travellers visiting high-prevalence countries, healthcare workers, people who inject drugs, those with chronic liver or kidney disease, and individuals at risk through sexual contact. In the UK, the standard course consists of three doses given over six months, though an accelerated schedule is available for those who need protection more quickly. A completed three-dose course provides long-term and likely lifelong protection for most people, with a booster only recommended in specific circumstances such as ongoing occupational exposure. Antibody testing following vaccination can confirm whether protective immunity has been achieved, and is recommended for certain high-risk groups including healthcare workers.
How is Hepatitis B Transmitted?
Hepatitis B is a viral liver infection caused by the hepatitis B virus (HBV), a member of the Hepadnaviridae family. It is one of the most significant infectious diseases in the world — more common than HIV and many times more infectious — yet it remains widely underdiagnosed and undertreated in the UK and globally. The virus causes both acute and chronic infection, with the risk of developing chronic disease being inversely related to age at the time of infection: approximately 90% of infants infected at birth develop chronic hepatitis B, compared to fewer than 5% of adults who contract the infection.
Understanding how hepatitis B is transmitted is essential for appreciating who is at risk and why vaccination is so important. Hepatitis B is a bloodborne virus, but it is also transmitted through other body fluids including semen, vaginal secretions, and breast milk. It is significantly more infectious than HIV — the hepatitis B virus can survive outside the body on surfaces for up to seven days, which has important implications for both household and healthcare settings.
How Hepatitis B is Transmitted
–> Unprotected sexual intercourse with an infected person — hepatitis B is one of the most common sexually transmitted infections worldwide.
–> Sharing needles, syringes, or other drug-injecting equipment with an infected person.
–> Mother to baby during childbirth (vertical transmission) — a major route of transmission in high-prevalence countries.
–> Needlestick injuries or other exposure to infected blood in healthcare settings.
–> Sharing personal items that may carry traces of infected blood, such as razors, toothbrushes, or nail clippers.
–> Unsterile tattooing, body piercing, or medical and dental procedures in countries with inadequate infection control standards.
–> Blood transfusions in countries where blood is not routinely screened for hepatitis B.
It is important to note that hepatitis B is not spread through casual contact — sharing food or drinks, hugging, coughing, sneezing, or using the same toilet as an infected person does not transmit the virus. This distinction is important for reducing the stigma associated with the infection and for helping people understand their own risk accurately.
The Global Burden of Hepatitis B
Hepatitis B is a global public health emergency of significant proportions. According to the WHO Global Hepatitis Report 2024, an estimated 254 million people are living with chronic hepatitis B infection worldwide, with approximately 1.2 million new infections occurring each year. The disease is hyperendemic in sub-Saharan Africa and the Western Pacific region, where between 5% and 10% of the adult population carries the virus, compared to less than 1% in the UK and other low-prevalence countries. Despite the existence of a safe, effective, and affordable vaccine for over four decades, hepatitis B remains one of the leading causes of preventable death worldwide.
Chronic hepatitis B infection is responsible for approximately 1.1 million deaths annually, the majority of which result from cirrhosis — severe scarring of the liver — and hepatocellular carcinoma, the most common form of primary liver cancer. Hepatitis B is in fact one of the leading causes of liver cancer globally, responsible for around 30% of all cases. The economic burden of chronic hepatitis B is also immense, placing enormous pressure on healthcare systems in high-prevalence countries. Vaccination is the single most cost-effective intervention available for reducing this burden, and the WHO has set a target of eliminating hepatitis B as a public health threat by 2030.
Who Should Get the Hepatitis B Vaccine?
In the UK, the hepatitis B vaccine is now part of the routine childhood immunisation schedule, delivered as part of the 6-in-1 combination vaccine at eight, twelve, and sixteen weeks of age. However, a significant proportion of adults in the UK were not vaccinated as children and may be at risk of hepatitis B infection through a range of occupational, lifestyle, and travel-related factors. The following groups are recommended by UKHSA to receive hepatitis B vaccination.
Groups Recommended to Receive Hepatitis B Vaccination in the UK
–> Healthcare workers and others whose occupation may expose them to blood or blood-stained body fluids, including laboratory staff, morticians, and emergency service workers.
–> Travellers visiting countries with a high or intermediate prevalence of hepatitis B, particularly those who may receive medical or dental treatment, have unprotected sexual contact, or engage in activities that carry a risk of blood exposure.
–> People who inject drugs, or whose sexual partners inject drugs.
–> Men who have sex with men (MSM) and others with multiple sexual partners or whose sexual behaviour puts them at increased risk.
–> Close household or sexual contacts of people with chronic hepatitis B infection.
–> People with chronic liver or kidney disease, including those on haemodialysis.
–> People with haemophilia or other conditions requiring frequent administration of blood products.
–> Prisoners and residents of long-stay care facilities.
–> Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive.
–> Individuals travelling to or from adoption agencies in high-prevalence countries.
If you are unsure whether you fall into one of these at-risk categories, a consultation with a GPhC-regulated pharmacist at Perfect Meds can help you assess your individual risk and determine whether hepatitis B vaccination is recommended for your personal circumstances.
Unsure whether you need the hepatitis B vaccine? Our expert pharmacists can help you find out. Call us to get a personalised vaccination assessment.
How the Hepatitis B Vaccine Works
The hepatitis B vaccine is a recombinant subunit vaccine — meaning it does not contain live virus but instead uses a small piece of the hepatitis B virus surface protein (known as hepatitis B surface antigen, or HBsAg) to stimulate the immune system to produce protective antibodies. Because the vaccine does not contain any live or whole virus, it cannot cause hepatitis B infection and is considered very safe for most people, including those who are immunocompromised, pregnant, or breastfeeding.
Upon vaccination, the immune system recognises the surface protein as foreign and mounts an immune response, producing antibodies against it. These antibodies remain in the body long after vaccination — and the immune system retains a memory of the hepatitis B surface antigen, meaning that if it ever encounters the real virus, it can respond rapidly to neutralise it before infection becomes established. This immunological memory is the basis of the long-term and likely lifelong protection that a completed hepatitis B vaccine course provides for most recipients.
Hepatitis B Vaccines Available in the UK
Several hepatitis B vaccine products are licensed for use in the UK, available either as standalone hepatitis B vaccines or in combination with other antigens. The most commonly used standalone hepatitis B vaccines in the UK are Engerix B and HBVAXPRO. A combination vaccine called Twinrix is also available, which provides protection against both hepatitis A and hepatitis B in a single injection and is a popular and convenient option for travellers who require protection against both diseases.
The Hepatitis B Vaccination Schedule
The standard hepatitis B vaccination schedule in the UK for adults and children over fifteen years consists of three doses given over a period of six months. The first dose is given at the chosen start date, the second dose one month later, and the third dose five months after the second — giving a total course duration of six months. This standard schedule consistently produces high levels of protective antibody in the vast majority of healthy recipients and is the recommended approach for those who are not under time pressure before travel or occupational risk exposure.
An accelerated hepatitis B vaccination schedule is available for those who need protection more quickly, such as travellers with an imminent departure date or individuals who have recently experienced a potential exposure to the virus. The accelerated schedule delivers doses at zero, one, and two months, with a fourth booster dose given at twelve months to consolidate long-term immunity. In some clinical situations, a super-accelerated schedule delivering doses at zero, seven, and twenty-one days may be used, with a booster at twelve months. The table below summarises the available hepatitis B vaccination schedules and their key characteristics.
| Schedule | Dose Timing | Booster Required | Best Suited For | Protection Onset |
|---|---|---|---|---|
| Standard | 0, 1, and 6 months | Not routinely required | Most adults and children not under time pressure | After dose 2 (partial); full after dose 3 |
| Accelerated | 0, 1, and 2 months + booster at 12 months | At 12 months | Travellers with medium-term departure; occupational risk | After dose 2 (partial); full after dose 3 |
| Super-Accelerated | 0, 7, and 21 days + booster at 12 months | At 12 months | Imminent travel; post-exposure prophylaxis | Partial after dose 2; consolidate at 12 months |
| NHS Childhood Schedule | 8, 12, and 16 weeks (as part of 6-in-1) | Not routinely required | Infants born from August 2017 onwards | Full after 3-dose primary course |
| Twinrix (Hep A + Hep B) | 0, 1, and 6 months | Hepatitis A booster at year 6–12 | Travellers needing both hepatitis A and B protection | Full after 3-dose course |
How Long Does the Hepatitis B Vaccine Last?
One of the most commonly asked questions about the hepatitis B vaccine is how long its protection lasts. The evidence strongly indicates that most healthy individuals who complete the full three-dose primary course can expect long-term and likely lifelong protection against hepatitis B. Studies have followed vaccinated individuals for over thirty years and found that, even when detectable antibody levels have waned over time, the immune system retains a memory response that is capable of mounting a rapid and effective defence against hepatitis B exposure. This immunological memory appears to persist even when antibody levels fall below the threshold conventionally considered protective (10 mIU/mL).
As a result, UKHSA guidance does not recommend routine booster doses of the hepatitis B vaccine for the general population following a completed primary course. However, there are specific circumstances in which ongoing monitoring and potentially booster doses are recommended. Healthcare workers and others with ongoing occupational risk are recommended to have their antibody levels tested following completion of the primary course, and to receive a booster dose if levels are found to be below the protective threshold. Those on haemodialysis may also require higher doses or more frequent boosters due to the reduced immune response associated with kidney failure.
When a Hepatitis B Booster May Be Recommended
–> Healthcare workers and laboratory staff who have ongoing occupational exposure to blood and body fluids — antibody titre testing is recommended following the primary course and at regular intervals thereafter.
–> Individuals on haemodialysis — reduced immune response in kidney failure may necessitate higher vaccine doses and more frequent boosters to maintain protective immunity.
–> Immunocompromised individuals — those receiving immunosuppressive therapy or with conditions that impair immune function may mount a suboptimal response to the primary course and may require additional doses.
–> Those who were identified as non-responders following their primary course — approximately 5 to 10% of healthy adults under 40 do not achieve protective antibody levels after three doses, with rates rising significantly with age. A repeat course may be beneficial and should be discussed with a pharmacist or GP.
–> Following a potential hepatitis B exposure — a booster may be recommended as part of post-exposure prophylaxis, depending on the individual’s antibody status at the time of exposure.
Hepatitis B Vaccination for Travellers
Hepatitis B is endemic in many of the world’s most popular travel destinations. Countries with high or intermediate prevalence of hepatitis B include large parts of sub-Saharan Africa, Southeast Asia, South Asia, the Western Pacific, Eastern Europe, and Central Asia. The level of hepatitis B exposure risk for travellers visiting these regions is closely linked to the specific activities they engage in during their trip. Those who may receive medical or dental treatment abroad, engage in unprotected sexual activity with local residents, have body piercings or tattoos performed in unregulated settings, or take part in activities that carry a risk of injury and subsequent blood exposure are all at heightened risk and should be vaccinated before travel.
Even travellers who do not consider themselves to be engaging in high-risk behaviour are encouraged to consider hepatitis B vaccination before visiting high-prevalence regions, as unexpected medical emergencies can always arise during travel and the standard of blood screening and infection control in some healthcare settings abroad cannot always be guaranteed. The combination Twinrix vaccine, which provides protection against both hepatitis A and hepatitis B, is a particularly practical option for travellers who require both vaccines — reducing the number of injections required and simplifying the pre-travel vaccination process.
Knowing which vaccinations are recommended for your specific destination is the first step towards travelling safely and with complete peace of mind. Enter your destination below to get an instant overview of the travel vaccines that may be recommended for your trip, including whether hepatitis B vaccination should form part of your pre-travel health plan:
Travellers heading to a high-prevalence hepatitis B region should make sure their vaccination is in place well before departure. Contact us to book a consultation with Perfect Meds today and set off knowing you are fully protected.
Hepatitis B Vaccination in Pregnancy and for Newborns
Hepatitis B poses a particularly serious risk during pregnancy because of the high likelihood of transmission from mother to baby during childbirth. Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive have a significantly elevated risk of developing chronic hepatitis B infection — in the absence of intervention, up to 90% of infants born to highly infectious mothers (those who are both HBsAg and hepatitis B e antigen positive) will develop chronic infection. This is why all pregnant women in the UK are routinely screened for hepatitis B as part of the antenatal booking blood tests.
Infants born to HBsAg-positive mothers receive an accelerated hepatitis B vaccination schedule beginning at birth, alongside hepatitis B immunoglobulin (HBIG) — an antibody preparation that provides immediate short-term protection whilst the vaccine-induced immune response develops. This combination of active and passive immunisation is highly effective at preventing mother-to-child transmission of hepatitis B when given promptly after birth. The hepatitis B vaccine is considered safe during pregnancy when the risk of hepatitis B exposure is significant, and a healthcare professional can advise on the risk-benefit assessment in individual cases.
Hepatitis B Vaccine Safety and Side Effects
The hepatitis B vaccine has one of the most extensive and well-documented safety records of any vaccine in clinical use. It has been administered to billions of people worldwide over more than four decades, and large-scale surveillance studies have consistently confirmed its safety across all age groups, including infants, pregnant women, and immunocompromised individuals. The vaccine does not contain live virus and cannot cause hepatitis B infection.
Common Side Effects of the Hepatitis B Vaccine
–> Soreness, redness, or mild swelling at the injection site — the most frequently reported reaction, typically resolving within two to three days.
–> Mild headache, fatigue, or low-grade fever in a small proportion of recipients, usually resolving within 24 to 48 hours.
–> Occasionally, mild nausea or gastrointestinal discomfort following vaccination.
–> Serious allergic reactions (anaphylaxis) are extremely rare and typically occur within 15 to 30 minutes of vaccination — remaining at the vaccination centre for this period after each dose is advisable.
The hepatitis B vaccine does not cause chronic fatigue syndrome, multiple sclerosis, or other conditions that have been speculatively linked to it in the past — extensive independent research has found no credible evidence for any of these associations. The safety profile of the hepatitis B vaccine is considered excellent, and the benefits of vaccination far outweigh the very small risks associated with it for almost all individuals.
Non-Responders to the Hepatitis B Vaccine
Approximately 5 to 10% of healthy adults under 40 do not achieve protective levels of hepatitis B surface antibody (anti-HBs) following a standard three-dose primary course — a phenomenon known as non-response. Non-response rates rise significantly with age, reaching up to 50% in those over 60, which makes age an important factor when planning vaccination and interpreting antibody test results. Non-response is also more common in those who are overweight, smokers, those with underlying immunosuppression, and those who received injections in the buttock rather than the deltoid muscle of the upper arm (which can reduce vaccine efficacy). Non-response does not mean that vaccination has been entirely without effect — some degree of immunological memory may still have been established — but it does indicate that additional steps may be needed to achieve confirmed protective immunity.
Those identified as non-responders after antibody testing following their primary course are typically recommended to complete a further three-dose course, with additional antibody testing carried out afterwards to evaluate whether protective immunity has been achieved. A proportion of initial non-responders will achieve protective immunity following a repeat course. Those who remain non-responders after a second full course are considered persistent non-responders and should be counselled about their hepatitis B status, advised to take precautions against exposure, and offered appropriate monitoring if they are in an occupational risk group. Post-exposure prophylaxis with hepatitis B immunoglobulin should be considered promptly for persistent non-responders who experience a potential exposure to hepatitis B.
Frequently Asked Questions
From understanding who needs the hepatitis B vaccine to knowing how many doses are required and whether your protection is still current, these answers to the most common questions will help you make a confident and well-informed decision about your vaccination.
Is the hepatitis B vaccine available on the NHS?
The hepatitis B vaccine is available free on the NHS for individuals who meet specific eligibility criteria, including healthcare workers, people who inject drugs, those with chronic liver or kidney disease, and infants born to hepatitis B-positive mothers. For those who do not meet NHS eligibility criteria — including most travellers — the vaccine is available privately through registered pharmacies and travel clinics such as Perfect Meds.
How do I know if I am already immune to hepatitis B?
A blood test known as a hepatitis B surface antibody (anti-HBs) test can confirm whether you have protective levels of immunity against hepatitis B, either from prior vaccination or from previous infection that has resolved. If you are unsure of your vaccination history or immune status, a pharmacist can arrange antibody testing and advise on whether vaccination or a booster is required based on the results.
Can I have the hepatitis B vaccine at the same time as other vaccines?
Yes — the hepatitis B vaccine can be given simultaneously with most other vaccines, including those routinely used in travel health, without any reduction in efficacy or increased risk of side effects. In fact, combination vaccines such as Twinrix, which protects against both hepatitis A and hepatitis B, are specifically designed to be given as a single injection covering both diseases.
Is the hepatitis B vaccine suitable for people who are immunocompromised?
Yes — because the hepatitis B vaccine does not contain live virus, it is safe for immunocompromised individuals, including those receiving immunosuppressive therapy, those living with HIV, and those who have had organ transplants. However, immunocompromised individuals may mount a reduced immune response to the standard vaccine course and may require higher doses, additional doses, or more frequent antibody monitoring to confirm protective immunity.
What is the difference between hepatitis A and hepatitis B?
Hepatitis A and hepatitis B are both liver infections caused by different viruses with very different transmission routes and clinical outcomes. Hepatitis A is spread primarily through contaminated food and water, causes acute illness only, and does not lead to chronic infection, whilst hepatitis B is spread through blood, sexual contact, and from mother to child, and can cause both acute and chronic liver disease including cirrhosis and liver cancer.
Do I need antibody testing after completing the hepatitis B vaccine course?
Routine post-vaccination antibody testing is not recommended for everyone, but is strongly advised for healthcare workers, those on haemodialysis, immunocompromised individuals, and sexual contacts of hepatitis B-positive individuals, as these groups need confirmed evidence of protective immunity rather than simply completing the course. A pharmacist can advise on whether post-vaccination antibody testing is recommended for your individual circumstances and arrange the test if required.
Hepatitis B Vaccination — A Critical Step Towards Long-Term Liver Health
Hepatitis B is one of the most serious and most preventable infectious diseases in the world, and the hepatitis B vaccine is one of the safest, most effective, and most well-evidenced vaccines in clinical use. Whether you are a healthcare worker seeking occupational protection, a traveller planning a trip to a high-prevalence region, someone in an at-risk lifestyle group, or simply an adult who was not vaccinated as part of the NHS childhood programme and wants to protect themselves, hepatitis B vaccination is a straightforward, well-tolerated, and genuinely life-saving investment in your long-term health.
From determining who needs the hepatitis B vaccine and identifying the most suitable dosing schedule to arranging post-vaccination antibody testing, the team at Perfect Meds has the expertise to answer every question you may have. Our GPhC-regulated pharmacists provide expert, personalised hepatitis B vaccination services — from initial risk assessment and vaccine administration through to post-vaccination antibody testing and ongoing advice — all in a convenient, accessible, and professional setting. Book now to arrange your hepatitis B vaccination consultation at Perfect Meds and take a definitive step towards protecting your liver health for the long term.
Medical Disclaimer: The information provided in this article is intended for general informational purposes only and does not constitute medical advice. Individual circumstances vary, and you should always speak to a qualified medical professional or pharmacist before starting any vaccination, treatment, or health programme. If you have any concerns about your health or suitability for any vaccine, please consult your GP or a registered healthcare provider before proceeding.
